Low-dose ethinylestradiol/levonorgestrel

Drugs

Volumn 65, Issue 16, 2005, Pages 2299-2306

  Dando, Toni M ^a   Curran, Monique P ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; ASCORBIC ACID; CYCLOSPORIN; ETHINYLESTRADIOL PLUS LEVONORGESTREL; ETHINYLESTRADIOL PLUS LYNESTRENOL; FLUCONAZOLE; HERBACEOUS AGENT; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HYPERICUM PERFORATUM EXTRACT; INDINAVIR; ITRACONAZOLE; LEIOS; MORPHINE; PARACETAMOL; SALICYLIC ACID; TEMAZEPAM; TROLEANDOMYCIN;

ABDOMINAL PAIN; ACNE; ALLERGIC REACTION; BIOAVAILABILITY; BREAKTHROUGH BLEEDING; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; DEPRESSION; DYSMENORRHEA; HEADACHE; HEART INFARCTION; HUMAN; LIPID BLOOD LEVEL; MASTALGIA; MENSTRUAL CYCLE; MENTAL INSTABILITY; METRORRHAGIA; MIGRAINE; NAUSEA; ORAL CONTRACEPTION; OVARY FUNCTION; OVULATION; PREGNANCY; PREGNANCY RATE; REVIEW; THROMBOEMBOLISM; URTICARIA; VOMITING; WEIGHT GAIN;

CONTRACEPTIVES, ORAL, COMBINED; ETHINYL ESTRADIOL; FEMALE; HUMANS; LEVONORGESTREL;

HUMAN IMMUNODEFICIENCY VIRUS; HYPERICUM PERFORATUM;

EID: 27644508060     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200565160-00007     Document Type: Review

References (18)

1. Skouby SO. Contraceptive use and behavior in the 21st century: a comprehensive studt across five European countries. Eur J Contracept Reprod Health Care 2004; 9: 57-68
2. Mosher WD, Martinez GM, Chandra A, et al. Use of contraception and use of family planning services in the United States: 1982-2002. Hyattsville (MD): National Institutes of Health, National Center for Health Statistics, 2004. Advance Data From Vital and Health Statistics. Report no.: 350
3. Borgelt-Hansen L. Oral contraceptives: an update on health benefits and risks. J Am Pharm Assoc 2001 Nov; 41 (6): 875-86
4. Archer DF, Maheux R, DelConte A, et al. Efficacy and safety of a low-dose monophasic combination oral contraceptive containing 100 μg levonorgestrel and 20 μg ethinyl estradiol (Alesse®): North American Levonorgestrel Study Group (NALSG). Am J Obstet Gynecol 1999 Nov; 181: S39-44
5. Wyeth Pharmaceuticals Inc. Alesse® 28 tablets (levonorgestrel and ethinyl estradiol tablets): US prescribing information 2004 Apr [online]. Available from URL: http://www.wyeth.com [Accessed 2005 Sep 7]
6. Teichmann A, Martens H, Bordasch C, et al. The effects of a new low-dose combined oral contraceptive containing levonorgestrel on ovarian activity. Eur J Contracept Reprod Health Care 1996; 1 (3): 246-56
7. Coney P, DelConte A. The effects on ovarian activity of a monophasic oral contraceptive with 100 μg levonorgestrel and 20 μg ethinyl estradiol. Am J Obstet Gynecol 1999 Nov; 181: S53-58
8. Young RL, DelConte A. Effects of low-dose monophasic levonorgestrel with ethinyl estradiol preparation on serum lipid levels: a twenty-four month clinical trial. Am J Obstet Gynecol 1999; 181: S59-62
9. Reisman H, Martin D, Gast MJ. A multicenter randomized comparison of cycle control and laboratory findings with oral contraceptive agents containing 100 μg levonorgestrel with 20 μg ethinyl estradiol or triphasic norethindrone with ethinyl estradiol. Am J Obstet Gynecol 1999; 181: S45-52
10. Archer DF, Mammen EF, Grubb GS. The effects of a low-dose monophasic preparation of levonorgestrel and ethinyl estradiol on coagulation and other hemostatic factors. Am J Obstet Gynecol 1999 Nov; 181: S63-66
11. Rosenberg MJ, Meyers A, Roy V. Efficacy, cycle control, and side effects of low- and lower-dose oral contraceptives: a randomized trial of 20 μg and 35 μg estrogen preparations. Contraception 1999; 60: 321-9
12. Carr BR, DelConte A. Using a low-dose contraceptive in women 35 years of age and over: 20 μg estradiol/100 μg levonorgestrel. Contraception 2002 Jun; 65: 397-402
13. Davis AR, Westhoff C, O'Connell K, et al. Oral contraceptives for dysmenorrhea in adolescent girls: a randomized trial. Obstet Gynecol 2005 Jul; 106: 97-104
14. Coney P, Washenik K, Langley RGB, et al. Weight change and adverse event incidence with a low-dose oral contraceptive: two randomized, placebo-controlled trials. Contraception 2001 Jun; 63: 297-302
15. Archer DF, Maheux R, DelConte A, et al. A new low-dose monophasic combination oral contraceptive (Alesse™) with levonorgestrel 100 μg and ethinyl estradiol 20 μg: North American Levonorgestrel Study Group (NALSG). Contraception 1997 Mar; 55 (3): 139-44
16. The European Agency for the Evaluation of Medicinal Products. EMEA Committee for Proprietary Medicinal Products public assessment report - combined oral contraceptives and venous thromboembolism 2001 Sep 28 [online]. Available from URL: http://www.emea.eu.int/pdfs/human/regaffair/0220101en.pdf [Accessed 2005 Oct 4]
17. DelConte A, Loffer F, Grubb GS. Cycle control with oral contraceptives containing 20 μg of ethinyl estradiol: a multicenter, randomized comparison of levonorgestrel/ethinyl estradiol (100 μg/20 μg) and norethindrone/ethinyl estradiol (1000 μg/20 μg). Contraception 1999; 59 (3): 187-93
18. Chavez A, DelConte A. A comparison of cycle control with monophasic levonorgestrel/ethinylestradiol 100 μg/20 μg versus triphasic norethindrone/ethinylestradiol 500-750-1000 μg/35 μg: a multicenter, randomized, open-label study. Eur J Contracept Reprod Health Care 1999 Jun; 4 (2): 75-83